Last updated: April 23, 2026
Who supplies oxazepam APIs used in finished products?
Oxazepam is a benzodiazepine intermediate-grade to finished-grade API commodity in many markets. Supplier coverage typically splits into (1) API manufacturers that sell oxazepam drug substance and (2) contract manufacturers (CMOs) that convert drug substance into tablets/capsules under marketing authorization.
Common supplier archetypes by role (commercially used in procurement):
- API manufacturers (drug substance): Produce oxazepam API under GMP, supply to brand owners and CMO packagers.
- Intermediates and synthesis-capable firms: Supply upstream intermediates or execute full synthesis for APIs under contract, then ship API under their GMP process.
- Finished-dose packagers/CMOs: Buy oxazepam API and formulate, compress, coat, and package tablets for branded and generic markets.
- Packagers under marketing licenses: Often do final packaging and labeling; sourcing of API may be internal or via approved API vendors.
Which companies commonly show up as oxazepam API/finished-dose suppliers in procurement channels?
The oxazepam market is dominated by established generics and CDMO supply chains. In practice, procurement shortlists usually include large Indian generics and European/US-oriented intermediates and CMOs that maintain multiple benzo-synthesis and solid-dose capabilities.
Supplier lists are not a single static set across all countries because oxazepam is regulated and supply eligibility depends on the filing country, local GMP status, and controlled-substance handling requirements. As a result, vendor “availability” changes by destination market and licensing.
API and CMO procurement targets (supplier archetypes used by buyers)
Below is a procurement-ready structure for identifying who supplies oxazepam in the real market. It maps to how approvals and supply agreements are typically executed, not to a universal global roster.
| Buyer need |
Typical supplier category |
Proof point buyers validate |
| Drug substance for tablets |
Oxazepam API manufacturer or synthesis contractor |
GMP certificate scope for oxazepam/API manufacturing; DMF/ASMF (where applicable); CoA batch testing |
| Formulation and packaging |
CMO solid oral-dose site |
Manufacturing authorization for the dosage form; validated process for tablet/capsule; stability program |
| Market-specific packaging |
Local packager / marketing authorization holder (MAH) supply chain |
Country registration; labeling and distribution license; controlled logistics capability |
| Emergency supply / multi-source |
Multiple API vendors |
Ability to dual-source with identical specs (impurities, polymorph if relevant) |
How to identify approved suppliers for oxazepam in practice
Procurement and regulatory teams typically converge on one of two paths:
Path A: DMF/ASMF-backed API supply
- Buyers request DMF/ASMF references (where used) and verify that oxazepam is covered within the certificate and documentation.
- They verify the site manufacturing authorization, then lock CoA specs and impurity limits.
Path B: Finished-dose sourcing via approved MAHs/CMOs
- Buyers source the finished dosage form directly from a CMO/MAH network.
- They validate that the dosage strength (e.g., 10 mg tablets or other registered strengths) is manufactured under the approved process, then negotiate contract manufacturing.
Which oxazepam strengths and dosage forms do suppliers typically support?
Most procurement requests center on solid oral dosage forms, most commonly tablets, with strength dictated by local registrations and historical markets.
Common finished-dose format patterns:
- Tablets (often the dominant commercial form)
- Capsules in certain jurisdictions or MAHs
- Strength selection varies by country registration (commonly 10 mg in several markets)
What specs and regulatory constraints govern oxazepam sourcing?
Oxazepam is a controlled benzodiazepine in many jurisdictions, so supplier qualification includes:
- GMP compliance for API and/or finished-dose manufacturing
- Impurity profile control aligned to pharmacopeia and product specs
- Controlled-substance logistics and recordkeeping
- Packaging controls to prevent mix-ups and ensure traceability
Supplier decision checklist for oxazepam
For business teams selecting suppliers, the practical gating items are:
- Manufacturing authorization and GMP scope covering oxazepam
- DMF/ASMF coverage (if part of the regulatory pathway for your destination)
- CoA format and impurity reporting against your target specification
- Stability program coverage for your dosage form (if buying finished tablets)
- Controlled substance handling capability for import/export and warehouse transfers
Key Takeaways
- Oxazepam supply is usually executed through API manufacturers and solid-dose CMOs, with regulatory qualification anchored on GMP scope and DMF/ASMF coverage where used.
- Supplier availability is market-specific because controlled-substance handling and local registration govern who can supply.
- The procurement standard is to qualify vendors by manufacturing authorization, CoA/impurity specs, stability, and controlled logistics, not by brand identity alone.
FAQs
-
Do oxazepam suppliers typically provide both API and finished tablets?
Some do, but many companies specialize either in API or in solid-dose manufacturing; dual sourcing often requires two vendors.
-
What is the most common finished dosage form sourced for oxazepam?
Tablets are the most common format in many regulated markets; capsules also exist depending on local registrations.
-
Why does oxazepam supplier eligibility vary by country?
Controlled-substance licensing, import/export controls, and local product registration restrict which sites can legally supply.
-
What documents are most important when qualifying an oxazepam API supplier?
GMP certificates scoped to oxazepam manufacturing, and DMF/ASMF or equivalent regulatory dossiers where applicable, plus CoAs with impurity reporting.
-
What procurement specs matter most for oxazepam?
Assay, impurities, residual solvents (if relevant), particle properties (if needed for solid-dose performance), and stability data tied to the dosage form.
References
[1] FDA. “Drug Master Files (DMF).” U.S. Food and Drug Administration. https://www.fda.gov/drugs/forms-submissions/drug-master-files-dmf
[2] European Medicines Agency (EMA). “Scientific guidelines and related documents for medicines.” European Medicines Agency. https://www.ema.europa.eu/en/documents/
[3] USP. “USP-NF General Notices and drug substance monographs.” United States Pharmacopeia. https://www.uspnf.com/
